Managing Severe Asthma in the Era of Biologics: Severe Persistent Eosinophilic Asthma

Tuesday, April 14, 2020, 8:00 AM - Wednesday, April 14, 2021, 11:59 PM

AMA PRA Category 1 Credits™ (0.50 hours), ABIM MOC Part 2 (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Among asthma patients, those with severe asthma represent the greatest area of unmet clinical need; however, the emergence of new targeted biologics has improved outcomes for some of these patients. This activity looks at when biologic therapies for severe asthma are warranted, reviews approaches to tailoring the most appropriate targeted biologic agent to patients with severe asthma based on their phenotype and endotype, and discusses strategies for navigating administrative challenges when prescribing biologic therapies.

At the end of the case, learners will play a round of Cranium Challenge to test their ability to apply what they have learned about incorporating biologic therapy for patients with severe asthma.

There are no fees for participating in and receiving CME credit for this online activity.

To view this activity, click here.

1. Recognize clinical characteristics that indicate a patient is a candidate for targeted biologic therapy;
2. Overcome challenges to implementing biologic therapy in practice;
3. Employ emerging data to differentiate the efficacy characteristics of biologic therapies and provide personalized treatment according to the phenotypic characteristics and outstanding clinical treatment needs of each patient.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

American Board of Internal Medicine

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity providers responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Medical Director & Program Planners

RedMedEd
Yvette Murley, PhD, Medical Director
Jonathan Simmons, Sr. Managing Editor
Karen Smith, Creative Director
Heather Rafa, Program Manager

University of Cincinnati Continuing Medical Education Office
Bruce Gebhardt, MD, Professor
Susan P. Tyler, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor RedMedEd, recommends the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or RedMedEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This educational activity is supported by an educational grant from GlaxoSmithKline.